Sirolimus for LAM Treatment
Safety and Durability of Sirolimus for Treatment of LAM
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- University of Cincinnati · Other
This trial is looking for male and female adults diagnosed with LAM. Participants will have the option to take sirolimus or other mTOR inhibitors as part of their treatment.
You may be able to join if
- I am 18 years old or older
- I have been diagnosed with LAM
- I can give informed consent
- I am currently on therapy or have been treated with mTOR inhibitors
You may not be able to join if
- I cannot attend at least one clinic visit per year
- I cannot give informed consent
- I am unable or unwilling to perform lung function tests
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Loading trial locations…